Live price temporarily unavailable.
Ovid Therapeutics (OVID) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | — | — | $12.6M | $208.4M | $1.50M | $392.0K | $566.0K | $7.25M |
| Growth (year over year) | — | — | — | — | — | +1551.6% | −99.3% | −73.9% | +44.4% | +1181.3% |
| Operating income | −$22.5M | −$65.0M | −$52.9M | −$61.4M | −$81.4M | $124.2M | −$55.5M | −$59.3M | −$61.9M | −$42.4M |
| Operating margin | — | — | — | — | −645.4% | 59.6% | −3696.4% | −15122.7% | −10933.7% | −585.2% |
| Net income | −$22.4M | −$64.8M | −$52.0M | −$60.5M | −$81.0M | $122.8M | −$54.2M | −$52.3M | −$26.4M | −$17.4M |
| Net margin | — | — | — | — | −642.3% | 58.9% | −3604.7% | −13351.8% | −4670.1% | −240.1% |
| EPS (diluted) | −$2.28 | −$3.35 | −$2.11 | — | −$1.39 | $1.76 | −$0.77 | −$0.74 | — | — |
| Balance sheet | ||||||||||
| Cash and equivalents | $51.9M | $87.1M | $36.5M | $41.9M | $72.0M | $187.8M | $44.9M | $27.0M | $26.3M | $13.2M |
| Total assets | $53.0M | $89.5M | $47.6M | $80.8M | $75.9M | $194.5M | $155.3M | $144.0M | $92.2M | $150.9M |
| Total liabilities | $3.73M | $6.02M | $8.84M | $10.8M | $32.3M | $14.8M | $23.0M | $56.2M | $23.9M | $20.3M |
| Shareholders' equity | $49.3M | $83.4M | $38.8M | $70.0M | $43.6M | $179.7M | $132.3M | $87.8M | $68.2M | $130.7M |
| Cash flow | ||||||||||
| Operating cash flow | −$17.8M | −$31.5M | −$45.6M | −$51.1M | −$51.6M | $118.6M | −$55.2M | −$45.8M | −$56.0M | −$38.3M |
| Capital expenditure | $30.4K | $38.9K | $33.9K | $57.2K | $127.2K | $184.0K | $1.22M | $40.0K | $71.0K | $0 |
| Free cash flow | −$17.8M | −$31.5M | −$45.6M | −$51.1M | −$51.7M | $118.4M | −$56.5M | −$45.8M | −$56.0M | −$38.3M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $173.0K | $76.0K | $130.0K | $6.27M | $132.0K | $718.0K | $0 | $733.0K |
| Growth (year over year) | +58.7% | −46.5% | −12.2% | +3611.2% | −23.7% | +844.7% | −100.0% | −88.3% |
| Operating income | −$13.2M | −$10.7M | −$12.6M | −$5.07M | −$12.5M | −$12.3M | −$17.8M | −$15.7M |
| Operating margin | −7645.1% | −14111.8% | −9653.8% | −80.9% | −9487.1% | −1712.1% | — | −2141.6% |
| Net income | −$14.0M | −$9.25M | −$10.2M | −$4.68M | −$12.2M | $9.66M | −$17.0M | −$15.0M |
| Net margin | −8096.0% | −12176.3% | −7873.1% | −74.7% | −9210.6% | 1345.8% | — | −2047.6% |
| EPS (diluted) | −$0.20 | — | — | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash and equivalents | $15.0M | $26.3M | $21.1M | $28.4M | $20.6M | $13.2M | $94.1M | $11.3M |
| Total assets | $102.7M | $92.2M | $81.7M | $77.4M | $63.8M | $150.9M | $225.6M | $232.0M |
| Total liabilities | $26.4M | $23.9M | $22.4M | $21.6M | $19.1M | $20.3M | $27.4M | $22.1M |
| Shareholders' equity | $76.3M | $68.2M | $59.3M | $55.8M | $44.7M | $130.7M | $198.3M | $209.9M |
| Cash flow | ||||||||
| Operating cash flow | −$15.0M | −$10.0M | −$10.3M | −$4.77M | −$12.9M | −$10.4M | −$13.9M | −$17.6M |
| Capital expenditure | −$4.00K | $22.0K | $0 | $0 | $0 | $0 | — | — |
| Free cash flow | −$15.0M | −$10.0M | −$10.3M | −$4.77M | −$12.9M | −$10.4M | — | — |
From Ovid Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Ovid Therapeutics in our feed yet.